Zook, Phillip <br/><br/>
Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Jan 2017 
 - 171-180 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1557-3265 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-16-0529  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Cell Line, Tumor<br/>Cell Survival--drug effects<br/>Disease Models, Animal<br/>Dose-Response Relationship, Drug<br/>Drug Evaluation, Preclinical<br/>Drug Synergism<br/>Gastrointestinal Stromal Tumors--drug therapy<br/>Gene Expression Profiling<br/>Heterocyclic Compounds, 3-Ring--pharmacology<br/>Humans<br/>Imatinib Mesylate--pharmacology<br/>Mice<br/>Protein Kinase Inhibitors--pharmacology<br/>Proto-Oncogene Proteins c-kit--antagonists & inhibitors<br/>Signal Transduction<br/>Survival Analysis<br/>Tumor Burden--drug effects<br/>Exome Sequencing<br/>Xenograft Model Antitumor Assays